These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21854846)

  • 1. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.
    Jornil J; Jensen KG; Larsen F; Linnet K
    Eur J Pharm Sci; 2011 Oct; 44(3):265-72. PubMed ID: 21854846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.
    Jornil J; Jensen KG; Larsen F; Linnet K
    Drug Metab Dispos; 2010 Mar; 38(3):376-85. PubMed ID: 20007670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
    Shulman RW; Ozdemir V
    Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
    Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
    J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative pharmacogenetics of nortriptyline: a novel approach.
    Kvist EE; Al-Shurbaji A; Dahl ML; Nordin C; Alván G; Ståhle L
    Clin Pharmacokinet; 2001; 40(11):869-77. PubMed ID: 11735606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
    Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
    DeVane CL; Gill HS
    J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe nortriptyline poisoning in poor metabolizers of the sparteine type].
    Petersen P; Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):443-4. PubMed ID: 2000655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
    Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
    Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence revisited: influence of age and sex on CYP enzymes.
    Bebia Z; Buch SC; Wilson JW; Frye RF; Romkes M; Cecchetti A; Chaves-Gnecco D; Branch RA
    Clin Pharmacol Ther; 2004 Dec; 76(6):618-27. PubMed ID: 15592333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
    Thapar MM; Ashton M; Lindegårdh N; Bergqvist Y; Nivelius S; Johansson I; Björkman A
    Eur J Clin Pharmacol; 2002 Apr; 58(1):19-27. PubMed ID: 11956669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
    Barter ZE; Tucker GT; Rowland-Yeo K
    Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
    Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
    J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power.
    Johnson TN; Kerbusch T; Jones B; Tucker GT; Rostami-Hodjegan A; Milligan PA
    Pharm Stat; 2009; 8(3):186-202. PubMed ID: 19291743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.